<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - FLUCLOXACILLIN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>FLUCLOXACILLIN</h1>

        <p><a href="../drugClass/PHP34546.html">PENICILLINS</a></p>

      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#effectOnLaboratoryTests" data-toggle="tab">Effect on laboratory tests</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Infections due to beta-lactamase-producing staphylococci including otitis externa</span>,
                <span class="indication">Adjunct in pneumonia</span>,
                <span class="indication">Adjunct in impetigo</span>,
                <span class="indication">Adjunct in cellulitis</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                250&#8211;500 mg 4 times a day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                250&#8211;500 mg every 6 hours.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                0.25&#8211;2 g every 6 hours.</li>
              <li class="dose child"><strong>For children 1 month&#8211;1 year</strong><br/>
                62.5&#8211;125 mg 4 times a day.</li>
              <li class="dose child"><strong>For children 2&#8211;9 years</strong><br/>
                125&#8211;250 mg 4 times a day.</li>
              <li class="dose child"><strong>For children 10&#8211;17 years</strong><br/>
                250&#8211;500 mg 4 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Endocarditis (in combination with other antibacterial if necessary)</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 85 kg)</strong><br/>
                8 g daily in 4 divided doses.</li>
              <li class="dose adult"><strong>For adults (body-weight 85 kg and above)</strong><br/>
                12 g daily in 6 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Osteomyelitis</span>,
            </h4>
            <p class="specificity"><span class="route">By slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Up to 8 g daily in 3&#8211;4 divided doses.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Surgical prophylaxis</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by slow intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1&#8211;2 g, to be administered up to 30 minutes before the procedure, then (by mouth or by intramuscular injection or by slow intravenous injection or by intravenous infusion) 500 mg every 6 hours if required for up to 4 further doses in high risk procedures.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Staphylococcal lung infection in cystic fibrosis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children </strong><br/>
                25 mg/kg 4 times a day (max. per dose 1 g), alternatively 100 mg/kg daily in 3 divided doses; maximum 4 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of <ph outputclass="organism"> <i> <i>Staphylococcus aureus</i> </i> </ph> lung infection in cystic fibrosis&#8212;primary prevention</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 1 month&#8211;3 years</strong><br/>
                125 mg twice daily.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prevention of <ph outputclass="organism"> <i> <i>Staphylococcus aureus</i> </i> </ph> lung infection in cystic fibrosis&#8212;secondary prevention</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children </strong><br/>
                50 mg/kg twice daily (max. per dose 1 g twice daily).</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">In adults</h3>
              <p>Reduce dose if eGFR less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">In children</h3>
              <p>Use normal dose every 8 hours if estimated glomerular filtration rate less than 10&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use</h3>
              <p>Accumulation of electrolytes can occur in patients with renal failure.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Gastrointestinal disturbances,
              </p>
              <p>
                <strong>veryRare:</strong> Cholestatic jaundice, hepatitis,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>For <i>intravenous infusion</i>, dilute reconstituted solution <i>in</i> Glucose 5% <i>or</i> Sodium Chloride 0.9% and give intermittently over 30&#8211;60 minutes.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Floxapen</i>
            <tm tmtype="reg"/>), give intermittently <i>in</i> Glucose 5% <i>or</i> Sodium chloride 0.9%; suggested volume 100&#8239;mL given over 30&#8211;60 minutes.</p><p>
            <i>via</i> drip tubing <i>in</i> Glucose 5% <i>or</i> Sodium chloride 0.9%; continuous infusion not usually recommended.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Flucloxacillin for bacterial infections</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/flucloxacillin-for-bacterial-infections">www.medicinesforchildren.org.uk/flucloxacillin-for-bacterial-infections</xref>
            </p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Hepatic disorders</h3>
              <p>Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. Healthcare professionals are reminded that:</p><ul>
            <li>flucloxacillin should not be used in patients with a history of hepatic dysfunction associated with flucloxacillin</li>
            <li>flucloxacillin should be used with caution in patients with hepatic impairment</li>
            <li>careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intravenous use:</strong>
            accumulation of electrolytes can occur with high doses
          </li>
          <li>
              <strong>With intravenous use:</strong>
            risk of kernicterus in jaundiced neonates when high doses given parenterally in neonates
          </li>
        </ul>
      </section>



      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">In adults</h3>
              <p>Flucloxacillin doses in the BNF may differ from those in product literature.</p>
            </section>
      </section>






      <section class="tab-pane" id="effectOnLaboratoryTests">
        <h2>Effect on laboratory tests</h2>

            <section class="effectOnLaboratoryTests">
              <p>False-positive urinary glucose (if tested for reducing substances).</p>
            </section>
      </section>




      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of FLUCLOXACILLIN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            infusion,

            <div id="PHP76449"><a href="../medicinalForm/PHP76449.html" data-target="#PHP76449" data-action="load">Capsule</a></div>
            <div id="PHP76458"><a href="../medicinalForm/PHP76458.html" data-target="#PHP76458" data-action="load">Oral solution</a></div>
            <div id="PHP76454"><a href="../medicinalForm/PHP76454.html" data-target="#PHP76454" data-action="load">Powder for solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
